Disease · MONDO_0015545
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Laboratory Parameters | 0 of 25 | 0 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Study Interruption Due to Safety Reasons | 1 of 25 | 1 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Withdrawal From the Study Due to Lack of Response | 0 of 25 | 0 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Adverse Events (AEs) (Serious and Non-serious). | 24 of 25 | 8 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Survival | 23 of 25 | 8 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Proportion of Subjects With Overall Response as Defined by CR or Partial Response (PR) | 16 of 25 | 6 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab | 11 of 25 | 4 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): deaths from any cause | 2 of 25 | 0 of 8 | 33 | NCT05001737 | Trial comparisons |
Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Number of Patients With Glucocorticoids (GC)s Tapering to a Dose Below 50% of Prednisolone (PDN) Equivalent at the Time of Emapalumab Start or to the Same (or Lower) Dose Being Administered Before the Occurrence of MAS Whichever Occurs First | 15 of 25 | 7 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): serious adverse events | 18 of 25 | 4 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): MAS Recurrence at Anytime After Achievement of CR | 4 of 21 | 1 of 7 | 28 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Number of Patients With GCs Tapering to ≤1mg/kg/Day of PDN Equivalent at Any Time Until End of Study (EOS). | 19 of 21 | 6 of 7 | 28 | NCT05001737 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015545/comparisons